Epeius Biotechnologies News from Send2Press Newswire

Epeius Biotechnologies News

News items related to Epeius Biotechnologies as issued by the Send2Press Newswire service on behalf of the noted news source.

Epeius Biotechnologies’ Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer

Wed, 17 Jun 2009, 06:00:17 EST | From: Epeius Biotechnologies Corporation

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009

Mon, 18 May 2009, 12:45:19 EST | From: Epeius Biotechnologies Corporation

SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S.

Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma

Mon, 04 Jun 2007, 15:53:00 EST | From: Epeius Biotechnologies Corporation

SAN MARINO, Calif. – June 4 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.